drugset / Trial / NCT04793399
Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients
Phase 1/2
Terminated
9 enrolled
Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica
Pfizer · collabRoche Farma, S.A · collab
NaSingle-groupOpen-labelTreatment
Summary
The combination of bosutinib plus atezolizumab in first line treatment in newly diagnosis chronic-phase Chronic Myeloid Leukemia (CML) patients could potentially increase molecular responses and therefore treatment discontinuation probabilities in these patients. We propose an Open-Label Phase Ib/II Study of Bosutinib in Combination with Atezolizumab for the Treatment of New Diagnosis Chronic Phase-Chronic Myeloid Leukemia Patients.
Timeline
- Start
- 2021-02-24
- Primary completion
- 2021-09-24
- Completion
- 2021-09-24
Outcome
Outcome not reported
Stopped: “The study has been prematurely terminated due to the onset of 2 dose limiting toxicities in 2 patients.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1680 mg | — |
| Subject | Bosutinib | Small molecule | 400 mg | Oral |